Cleared Special

miCOR System Lens Fragmentation System (K222236) - FDA 510(k) Clearance

Class II Ophthalmic device cleared through the Special 510(k) pathway - typically does not require clinical trials.

K222236 · Carl Zeiss Meditec Cataract Technology, Inc. · Ophthalmic device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Aug 2022
Decision
29d
Days
Class 2
Risk

K222236 is an FDA 510(k) clearance for the miCOR System Lens Fragmentation System. Classified as Unit, Phacofragmentation (product code HQC), Class II - Special Controls.

Submitted by Carl Zeiss Meditec Cataract Technology, Inc. (Reno, US). The FDA issued a Cleared decision on August 24, 2022 after a review of 29 days - a notably fast clearance cycle.

This device falls under the Ophthalmic FDA review panel, regulated under 21 CFR 886.4670 - the FDA ophthalmic device framework. As a Special 510(k), this submission covers a manufacturer modification to an existing cleared device rather than a new device introduction.

Device pattern: Iterative device modification. Low regulatory complexity profile. This Special 510(k) clearance confirms that the manufacturer's modifications remained within the established regulatory envelope of the original cleared device.

View all Carl Zeiss Meditec Cataract Technology, Inc. devices

Submission Details

510(k) Number K222236 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received July 26, 2022
Decision Date August 24, 2022
Days to Decision 29 days
Submission Type Special
Review Panel Ophthalmic (OP)
Summary Statement
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
81d faster than avg
Panel avg: 110d · This submission: 29d
Pathway characteristics
Modification to existing cleared device.

Device Classification

Product Code HQC Unit, Phacofragmentation
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 886.4670
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Ophthalmic devices follow this clearance model.

Regulatory Peers - HQC Unit, Phacofragmentation

All 24
Devices cleared under the same product code (HQC) and FDA review panel - the closest regulatory comparables to K222236.
Centurion™ Vision System (Active Sentry™) (8065753057)
K233902 · Alcon Laboratories, Inc. · Jan 2024
QUATERA 700
K230858 · Carl Zeiss Meditec, AG · Jul 2023
MICOR Lens Fragmentation System
K214028 · Carl Zeiss Meditec Cataract Technology, Inc. · Sep 2022
EVA NEXUS Ophthalmic Surgical System
K213467 · D.O.R.C. Dutch Ophthalmic Research Center (International) · Jun 2022
QUATERA 700
K212241 · Carl Zeiss Meditec, AG · Apr 2022
VERITAS Phacoemulsification Console, VERITAS Advanced Fluidics Pack and Advanced Infusion Pack, VERITAS Swivel Handpiece, VERITAS Advanced Foot Pedal, VERITAS Remote Control
K203060 · Johnson & Johnson Surgical Vision, Inc. · Mar 2021